Lallemand Biologicals GmbH, based in Wismar, is a wholly-owned subsidiary of the Spanish company Lallemand Bio S.L. and part of the Canadian Lallemand Group. The company specializes in the research, development, and production of biological plant protection products and biostimulants based on living fungal microorganisms. As a contract manufacturer within the Lallemand Plant Care Division, the company supplies both external customers and internal group sales entities. The Wismar site serves as a center of excellence for process development regarding the mass production of microorganisms.
Entwicklung, Anwendung bzw. Herstellung und Verwertung von Verfahren und Produkten bzw. Teilverfahren und Teilprodukten mit dem Ziel der Gesunderhaltung von landwirtschaftlichen und gärtnerischen Kulturen mittels biologischer Wirkprinzipien
Converted using the official Destatis and Eurostat correspondence tables; ISIC Rev. 4 is the United Nations' international industry classification.
This summary was generated with the help of AI. See our Data Quality Notice. Report error?
Source: German Commercial Register (Handelsregister) Schwerin Local Court, HRB 2884 (as of 18 November 2026)
| Name | Type | City |
|---|---|---|
| Daniel Karsch | Geschäftsführer(in) | Stäbelow |
Source: German Commercial Register (Handelsregister) Schwerin Local Court, HRB 2884 (as of 18 November 2026)
| Date | Event Type | Event |
|---|---|---|
| 07.12.2023 | Gesellschaftsvertrag amended | Gesellschaftsvertrag |
| 17.01.2022 | Company Name Change | Lallemand Biologicals GmbH |
| 06.07.2015 | Registered Seat Change | Wismar |
| Date | Type | Change | Total Capital |
|---|---|---|---|
| 23.08.2006 | Share Capital Set | — | 122.000 € |
Source: German Commercial Register (Handelsregister) Schwerin Local Court, HRB 2884 (as of 18 November 2026)
| Year | Revenue | Profit | Balance | Employees |
|---|---|---|---|---|
| 2026 | Gross profit€3.1M2 | -€127,748 | €12,026,866 | 57 |
| 2025 | €8,266,232 | -€1,585,243 | €14,386,106 | 59 |
| 2024 | €753,081 | -€262,765 | €15,696,142 | 61 |
| 2023 | €8,637,000 | -€825,641 | €14,721,244 | 56 |
| 2022 | €7,463,951 | -€61,184 | €15,433,988 | 50 |
| 2021 | €5,939,148 | €0 | €15,858,357 | 49 |
| 2020 | €5,139,673 | €0 | €17,207,039 | 55 |
| 2019 | €4,063,003 | €0 | €19,266,243 | — |
| 2013 | small company1 | €430,897 | €4,522,453 | — |
| 2012 | small company1 | €0 | €4,233,915 | — |
1 Small companies are not required to publish a profit-and-loss statement (§ 326 (1) HGB). The figure shown is the statutory ceiling under § 267 HGB where the balance-sheet total makes it binding — a company may exceed at most one of the three size criteria.
2 Gross profit under § 276 HGB: revenue less the cost of materials or cost of sales. Small and medium-sized companies may combine these items; revenue itself is then not disclosed and exceeds gross profit.
Source: German Company Register (Unternehmensregister) · Annual accounts
Sign in to download data
Source: German Commercial Register (Handelsregister) Schwerin Local Court, HRB 2884 (as of 18 November 2026)
INDICAL BIOSCIENCE GmbH
Leipzig · Herstellung von pharmazeutischen Spezialitäten und sonstigen pharmazeutischen Erzeugnissen
TÜV Rheinland Forschungs- und Innovationsmanagement GmbH
Köln · Forschung und Entwicklung im Bereich Rechts-, Wirtschafts- und Sozialwissenschaften sowie im Bereich Sprach-, Kultur- und Kunstwissenschaften
Phyton Biotech GmbH
Ahrensburg · Herstellung von pharmazeutischen Grundstoffen